IceCure Granted 180-Day Extension by Nasdaq for Compliance
IceCure Medical Ltd. received a 180-day extension from Nasdaq to meet the minimum bid price requirement after failing to do so within the initial compliance period. The company has until November 9, 2026, to regain compliance with Nasdaq’s rules, with the option of a reverse share split. This extension does not affect the trading of its shares on the Nasdaq Capital Market.
No Immediate Effect on Nasdaq Listing or Trading of the Company’s Ordinary Shares CAESAREA, Israel, May 13, 2026 /PRNewswire/ — IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys…